Brief: Oncolytics Biotech says Canadian Cancer Trials Group to present metastatic breast cancer study data
March 2 (Reuters) - Oncolytics Biotech Inc ONC.TO
* Oncolytics Biotech Inc. announces Canadian cancer trials
group to present final randomized data from phase 2 metastatic
breast cancer study at AACR 2017 annual meeting
Source text for Eikon: ID:nCNWh3V10a
Further company coverage: ONC.TO
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Announces Clinical Supply Agreement To Evaluate Pelareorep In Combination With Loqtorzi In Squamous Cell Anal Carcinoma
Brief: Oncolytics Says Pelareorep Shows Durable Survival Benefit in Anal Cancer
Brief: Oncolytics Biotech Expects Final Cohort 4 Results Of Goblet Study In Q4 2026
Brief: Oncolytics Biotech® Secures Patent Protection To Late 2040S And Provides Intellectual Property Portfolio Update
Brief: Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer